INTRODUCTION
60% of cases), in which the first symptoms develop at around 2 yr of age; a juvenile form (20-30% of cases), in which patients present with the symptoms between 3 and 16 yr of age; and an adult-onset form (15-20% of cases), with manifestations appearing after 16 yr of age [4] .
The late-infantile form is the most common type of MLD. Onset is characterized by ataxia and loss of acquired motor skills. Weakness and hypotonia are present in most patients, and disease progression is accompanied by mental deterioration until patients are no longer able to establish any contact with their surroundings. This form of MLD has a short course, and death generally occurs within 7 yr after onset [5] .
Some Korean cases of MLD have been reported, including 2 cases of the late-infantile form (one in a 2-yr-old girl, and another in a 4-yr-old girl), which showed typically clinical, neurologic, pathologic, and laboratory findings [6] [7] [8] .
The human ARSA gene maps to the long arm of chromosome 22, in the region of q13, and contains 8 exons that encode a 1521-nucleotide-long mRNA [3, 9] . More than 110 different mutations causing MLD have been identified in the ARSA gene in patients with various ethnic backgrounds worldwide [4] . However, thus far, no case of genetically confirmed MLD has been reported in Korea.
Here, we describe a Korean case of late-infantile MLD, with a novel ARSA splicing mutation as a causative factor.
CASE REPORT
A Korean male infant was one of the 2 children born to non-consanguineous parents. Pregnancy and labor progressed without complications. At the age of 3 months, 
DISCUSSION
MLD is a lysosomal storage disease caused by a deficiency in ARSA. It is characterized by the accumulation of sulfatide-the ARSA substrate-in the white matter of the central nervous system and in the peripheral nerves [11] . A pathological hallmark of the disease is demyelination, causing various ultimately lethal neurological symptoms [4] .
Patients homozygous for alleles that do not allow synthesis of functional ARSA always develop the most severe late-infantile form of the disease, whereas those homozygous for alleles allowing the expression of residual enzyme activity are associated with the later-onset juvenile or adult forms [4, 12, 13] . In this study, we report a compound heterozygous mutation in the ARSA gene in a patient with late-infantile onset MLD, with lethal clini- 
cal characteristics. An amino acid substitution of Asp for 99Gly resulted from a G-to-A transition in exon 2.
Because the substitution was from a neutral amino acid to an acidic one, the structure of the ARSA protein was thought to be possibly altered. In fact, a transient expression study by Kondo et al. [11] confirmed that such a mutation abolishes ARSA activity.
In addition, a mutation affecting the donor consensus splice site of intron 6, which was identified in this study, if MLD is in its late-infantile form [15, 16] . In this study, BMT was performed after the onset of symptoms. Best outcomes are noted in MLD patients who undergo BMT before the symptoms occur, slowing disease progression, although BMT does not seem to alleviate peripheral nervous system manifestations [14] . Therefore, identification of the disease-causing mutation can enable establishing a genotypic diagnosis of MLD, providing important information to both families and physicians.
This study identified a novel splicing mutation of the ARSA gene that was found to be related to late-infantile onset MLD with a lethal clinical course. Molecular diagnosis may be beneficial in the early diagnosis of MLD patients and for deciding intervention measures for their family members.
